Table 3. HLA-DQB1 alleles distribution in patients with type 1 diabetes and controls.
| DQB1 | T1D | Controls | OR | CI 95% | p | p |
|---|---|---|---|---|---|---|
| alleles | n (%) | n(%) | no-structured | structured | ||
| 201 | 423 (30.8%) | 156 (11.2%) | 3.52 | (2.88–4.31) | <0.0001 | <0.001 |
| 202 | 94 (6.9%) | 136 (9.8%) | 0.68 | (0.51–0.89) | 0.0051 | 0.008 |
| 301 | 140 (10.2%) | 189 (13.6%) | 0.72 | (0.57–0.91) | 0.0057 | 0.003 |
| 302 | 371 (27.0%) | 139 (10.0%) | 3.33 | (2.69–4.12) | <0.0001 | <0.001 |
| 303 | 27 (2.0%) | 32 (2.3%) | 0.85 | (0.51–1.43) | 0.5399 | 0.739 |
| 319 | 1 (0.1%) | 11 (0.8%) | 0.091 | (0.012–0.708) | 0.0041 | 0.0052 |
| 401 | 5 (0.4%) | 6 (0.4%) | 0.84 | (0.26–2.77) | 0.7773 | — |
| 402 | 32 (2.3%) | 81 (5.8%) | 0.38 | (0.25–0.58) | <0.0001 | <0.001 |
| 501 | 134 (9.8%) | 190 (13.7%) | 0.68 | (0.54–0.86) | 0.0014 | 0.007 |
| 502 | 30 (2.2%) | 51 (3.7%) | 0.59 | (0.37–0.93) | 0.0206 | 0.01 |
| 503 | 7 (0.5%) | 40 (2.9%) | 0.17 | (0.08–0.39) | <0.0001 | <0.001 |
| 601 | 6 (0.4%) | 8 (0.6%) | 0.76 | (0.26–2.19) | 0.6071 | 0.454 |
| 602 | 30 (2.2%) | 201 (14.5%) | 0.13 | (0.09–0.19) | <0.0001 | <0.001 |
| 603 | 16 (1.2%) | 90 (6.5%) | 0.17 | (0.09–0.29) | <0.0001 | <0.001 |
| 604 | 47 (3.4%) | 39 (2.8%) | 1.23 | (0.79–1.89) | 0.3518 | 0.691 |
| 609 | 4 (0.3%) | 12 (0.9%) | 0.335 | (0.108–1.042) | 0.0474 | |
| Others | 10 (0.7%) | 30 (2.2%) | ||||
| Total | 1372 | 1388 |
Association with Type 1 diabetes before and after correction for population stratification T1D = type 1 diabetes mellitus; n = number of individuals; OR = odds ratio; CI = confidence interval; p no-structured = level of significance before strat analysis; p structured = level of significance after strat analysis.
Sixteen alleles, with total number in patients plus controls greater than 10 (0.4%), were included. P required for statistical significance after Bonferroni correction for multiple tests <0.003. Rare alleles were included in others.